Incyte Secures U.S. Food and Drug Administration Approval for Jakafi XR
Incyte has announced a significant milestone with the approval of Jakafi XR™ (ruxolitinib) extended-release tablets by the U.S. Food and Drug Administration (FDA). This approval introduces a once-daily treatment option for patients living with certain chronic and life-altering hematologic conditions, including myelofibrosis (MF), polycythemia vera (PV), and graft-versus-host disease (GVHD).
Jakafi XR is a film-coated, extended-release formulation of Jakafi® (ruxolitinib), designed to simplify dosing while maintaining consistent therapeutic exposure. The new formulation reflects ongoing innovation aimed at improving patient convenience without compromising treatment outcomes.
The therapy will be available for pharmacy orders starting May 8, marking a rapid transition from approval to patient access.
Understanding Jakafi XR: Extended-Release Innovation
Jakafi XR is specifically engineered as a once-daily medication, offering an alternative to the twice-daily dosing required with the immediate-release (IR) version of Jakafi. Extended-release formulations are designed to release the active drug gradually over time, ensuring stable levels in the bloodstream throughout the day.
This advancement is particularly meaningful for patients managing chronic conditions, where adherence to treatment regimens plays a crucial role in achieving optimal outcomes. By reducing dosing frequency, Jakafi XR aims to make treatment routines more manageable.
Importantly, clinical data demonstrated that once-daily Jakafi XR provides consistent, day-long drug exposure comparable to the twice-daily immediate-release formulation. This means patients can expect similar efficacy with fewer daily doses.
Approved Indications and Patient Populations
The FDA has approved Jakafi XR for multiple indications, reflecting its broad utility in hematologic diseases:
- Myelofibrosis (MF): For adults with intermediate- or high-risk disease
- Polycythemia Vera (PV): For adults who have had an inadequate response to or are intolerant of hydroxyurea
- Graft-Versus-Host Disease (GVHD): For adults and children aged 12 years and older with steroid-refractory acute or chronic GVHD after failure of one or two lines of systemic therapy
These conditions often require long-term management and can significantly impact quality of life. The availability of a once-daily treatment option represents an important advancement for both patients and healthcare providers.
Leadership Perspective: Commitment to Hematology
According to Bill Meury, Chief Executive Officer of Incyte, the approval reinforces the company’s leadership in hematology and its focus on addressing evolving patient needs.
He emphasized that Jakafi XR expands treatment options by offering a once-daily alternative without altering the established role of Jakafi in clinical practice. This flexibility allows physicians to tailor treatment plans based on individual patient preferences and clinical considerations.
Incyte has long been recognized for its contributions to the treatment of myeloproliferative neoplasms (MPNs) and GVHD, and this approval further strengthens its position in the field.
Clinical Evidence: Bioequivalence and Efficacy
The FDA’s approval of Jakafi XR was supported by clinical data demonstrating bioequivalence between the extended-release and immediate-release formulations.
In a key study:
- A single 55 mg Jakafi XR tablet taken once daily was shown to be bioequivalent to
- A 25 mg immediate-release Jakafi tablet taken twice daily
Bioequivalence means that both formulations deliver the same active ingredient—ruxolitinib—at comparable levels in the body over time. This is assessed through pharmacokinetic measures such as steady-state drug exposure.
The findings indicate that Jakafi XR can provide similar clinical benefits to the original formulation while offering the convenience of once-daily dosing. For patients, this could translate into improved adherence and a more manageable treatment experience.
Safety Profile and Common Adverse Reactions
The safety of Jakafi XR is supported by extensive clinical studies of Jakafi across its approved indications. These studies included adult patients with myelofibrosis and polycythemia vera, as well as both adult and pediatric patients with acute and chronic GVHD.
The most common adverse reactions vary depending on the condition being treated:
For Myelofibrosis and Polycythemia Vera
- Low platelet counts (thrombocytopenia)
- Low red blood cell counts (anemia)
- Bruising
- Dizziness
- Headache
- Diarrhea
For Acute GVHD
- Low platelet counts
- Reduced red and white blood cell counts
- Infections
- Swelling
For Chronic GVHD
- Anemia
- Low platelet counts
- Infections, including viral infections
These side effects are consistent with the known safety profile of ruxolitinib and are generally manageable with appropriate monitoring and clinical care.
Expert Insights: Addressing Patient Needs
Dr. Naveen Pemmaraju, a leukemia specialist at The University of Texas MD Anderson Cancer Center, highlighted the challenges faced by patients living with chronic hematologic conditions.
He noted that many patients struggle with complex treatment regimens, particularly when managing multiple health issues. Simplifying dosing schedules can make a meaningful difference in daily life.
Dr. Pemmaraju also emphasized the transformative impact of ruxolitinib since its initial approval in 2011. The introduction of Jakafi XR builds on this legacy by providing an additional option that aligns with patient needs and preferences.
Researchers at MD Anderson have played a key role in advancing the clinical development of ruxolitinib, contributing to its widespread adoption in clinical practice.
Improving Treatment Adherence and Quality of Life
One of the key benefits of Jakafi XR lies in its potential to improve treatment adherence. Chronic conditions such as MF, PV, and GVHD often require long-term therapy, making it essential for patients to follow prescribed regimens consistently.
A once-daily tablet reduces the burden of remembering multiple doses, which can be particularly beneficial for patients with busy lifestyles or those managing several medications simultaneously.
Improved adherence is closely linked to better clinical outcomes, making this innovation not just a matter of convenience but also of therapeutic effectiveness.
Access and Availability: Supporting Patients
Incyte has confirmed that Jakafi XR will be available for pharmacy orders beginning May 8, ensuring timely access for patients following FDA approval.
To further support patients, the company offers the IncyteCARES program (Connecting to Access, Reimbursement, Education and Support). This comprehensive initiative provides:
- Financial assistance for eligible patients
- Help navigating insurance and reimbursement processes
- Educational resources about treatment
- Ongoing support services
Programs like IncyteCARES play a crucial role in reducing barriers to treatment, particularly for patients facing financial or logistical challenges.
The Broader Impact on Hematology Care
The approval of Jakafi XR reflects broader trends in healthcare toward patient-centric innovation. As treatments evolve, there is increasing emphasis on not only efficacy and safety but also convenience and quality of life.
Extended-release formulations are a key part of this shift, offering practical solutions that align with real-world patient needs. In the case of Jakafi XR, the ability to maintain therapeutic consistency while simplifying dosing represents a meaningful advancement.
For healthcare providers, the availability of multiple formulation options enables more personalized treatment approaches, improving the overall standard of care.
The FDA approval of Jakafi XR marks an important milestone in the treatment of myelofibrosis, polycythemia vera, and graft-versus-host disease. By combining proven efficacy with once-daily convenience, the new formulation addresses both clinical and practical aspects of patient care.
Incyte’s continued investment in innovation underscores its commitment to improving outcomes for patients with complex hematologic conditions. As Jakafi XR becomes available, it is expected to play a valuable role in enhancing treatment experiences and supporting long-term disease management.
Overall, Jakafi XR represents not just a new formulation, but a step forward in making effective therapies more accessible, manageable, and aligned with the needs of patients and healthcare providers alike.
About Myelofibrosis
Myelofibrosis (MF) is a part of a group of rare, chronic blood cancers called myeloproliferative neoplasms, or MPNs. MF occurs when a bone marrow defect results in an abnormal production of blood cells, causing scar tissue to form, which can lead to severe anemia, weakness, fatigue and an enlarged spleen and liver. MF can result from a progression of other bone marrow diseases, including polycythemia vera and essential thrombocythemia, or it can occur on its own.3
Polycythemia Vera (PV) is a part of a group of rare, chronic blood cancers called myeloproliferative neoplasms, or MPNs.3 PV occurs when bone marrow produces too many red blood cells, white blood cells and often platelets. Increased red blood cells and platelets can cause the blood to thicken, leading to an increased risk of blood clotting complications, including deep vein thrombosis, stroke or heart attack.4
Graft-versus-host disease (GVHD) is a condition that can occur after an allogeneic stem cell transplant (the transfer of stem cells from a donor) in which the donated cells initiate an immune response and attack the transplant recipient’s organs, leading to significant morbidity and mortality. There are two major forms of GVHD: acute, which generally occurs within 100 days of transplant, and chronic, which generally occurs after 100 days of transplant. Both forms can affect multiple organ systems, including the skin, gastrointestinal (digestive) tract and liver.5
